Insight report on PharmaPoint: Colorectal Cancer – US Drug Forecast and Market Analysis to 2023


“The Report PharmaPoint: Colorectal Cancer – US Drug Forecast and Market Analysis to 2023 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. –”

GlobalData has released its new PharmaPoint Country Evaluation report, PharmaPoint: Colorectal Cancer US Drug Forecast and Market Analysis to 2023. Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. In terms of targeted treatments, the metastatic CRC treatment landscape is mature, including the branded treatments Avastin (bevacizumab), Avastin (cetuximab), and Vectibix (panitumumab), treatments that have extended the survival of metastatic patients compared to chemotherapy-only regimens. However, high unmet needs remain for the extension of survival of metastatic patients, and particularly those with KRAS mutation-positive disease, for whom the epidermal growth factor receptor (EGFR) inhibitors Avastin and Vectibix are not recommended.

View Report At :

The US represents the largest market for CRC across the countries covered in this report. In 2013, GlobalDatas forecast estimates that sales of branded therapies were $2.23 billion. The US is the largest CRC market due to the high incidence of the disease, high drug treatment rate, and higher drug prices compared with the 5EU, Japan, and China. Increased sales of CRC therapies over the forecast period will be driven by increasing disease incident cases as the population ages, label extension of Stivarga as an adjuvant treatment for resected liver metastasis patients, and the launch of expensive new therapies that provide further treatment options for patients in later-line settings, replacing cheaper, generic chemotherapy-only regimens.

Download Sample copy of this Report at:


  • Overview of CRC including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

  • Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.

  • Sales forecast for the top drugs in the US from 2013-2023.

  • Analysis of the impact of key events as well the drivers and restraints affecting the US CRC market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return

  • Stay ahead of the competition by understanding the changing competitive landscape for CRC

  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

  • Make more informed business decisions from insightful and in-depth analysis of drug performance

  • Obtain sales forecast for drugs from 2013-2023 in the US

Table of Contents

1 Table of Contents 5

1.1 List of Tables 8

1.2 List of Figures 10

2 Introduction 11

2.1 Catalyst 11

2.2 Related Reports 12

2.3 Upcoming Related Reports 13

3 Disease Overview 14

3.1 Etiology and Pathophysiology 14

3.1.1 Etiology 14

3.1.2 Pathophysiology 16

3.2 Clinical Staging 17

3.3 Symptoms 19

4 Disease Management 20

4.1 Diagnosis and Treatment Overview 20

4.1.1 Screening and Diagnosis 20

4.1.2 Treatment Guidelines and Leading Prescribed Drugs 23

4.1.3 Clinical Practice 24

4.2 US 30

4.2.1 Screening and Diagnosis 32

4.2.2 Clinical Practice 33

5 Competitive Assessment 36

5.1 Overview 36

5.2 Product Profiles Major Brands 37

5.2.1 Avastin (Bevacizumab) 37

5.2.2 Erbitux (Cetuximab) 41

5.2.3 Vectibix (Panitumumab) 45

5.2.4 Stivarga (Regorafenib) 49

5.2.5 Zaltrap (Ziv-Aflibrcept) 53

5.2.6 Lonsurf (TAS-102) 56

5.2.7 Xeloda (Capecitabine) 60

6 Unmet Need and Opportunity 64

6.1 Overview 64

6.2 Therapies That Provide Substantial Overall Survival Benefit for Metastatic Patients 65

6.2.1 Unmet Need 65

6.2.2 Gap Analysis 67

6.2.3 Opportunity 67

6.3 Targeted Treatments for KRAS and BRAF Mutaton-Positive Patients 69

6.3.1 Unmet Need 69

6.3.2 Gap Analysis 70

6.3.3 Opportunity 70

6.4 Effective Neoadjuvant/Adjuvant Therapies for High Risk Resectable Disease 71

6.4.1 Unmet Need 71

6.4.2 Gap Analysis 72

6.4.3 Opportunity 72

6.5 Tolerable Later-Line Therapies For Chemotherapy-Resistant Patients 73

6.5.1 Unmet Need 73

6.5.2 Gap Analysis 73

6.5.3 Opportunity 74

Follow us on LinkedIn:

About us is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.


Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074